{"id":19,"date":"2025-01-28T18:37:20","date_gmt":"2025-01-28T18:37:20","guid":{"rendered":"https:\/\/mupages.marshall.edu\/sites\/valluri\/?page_id=19"},"modified":"2025-04-24T19:47:29","modified_gmt":"2025-04-24T19:47:29","slug":"publications","status":"publish","type":"page","link":"https:\/\/mupages.marshall.edu\/valluri\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"\n

1. ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial. Nature<\/strong> npj Precision. Oncology. 9, 86 (2025). <\/p>\n\n\n\n

    <\/ol>\n\n\n\n

    PDF<\/strong> : https:\/\/doi.org\/10.1038\/s41698-025-00874-0<\/a><\/p>\n\n\n\n

    2. A New and Effective Procedure for Advanced Oral Cancer Therapy: The Potential of a Cancer Stem Cell Assay in Guiding Chemotherapy. Transl Med<\/strong> UniSa. 2023 Dec 8;25(1):16-27. doi: 10.37825\/2239-9747.1042. PMID: 38143509<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    3) Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial. Cell Reports Medicine<\/strong> 2023 May 16;4(5):101025. doi: 10.1016\/j.xcrm.2023.101025. Epub 2023 May 2. PMID: 37137304<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    4) Treatment of unmethylated MGMT promoter recurrent glioblastoma with cancer stem cell assay-guided chemotherapy and the impact on patients\u2019 healthcare costs. Neurooncol Adv<\/strong>. 2023 May 12;5(1):vdad055. doi: 10.1093\/noajnl\/vdad055. eCollection 2023 Jan-Dec. PMID: 37287692<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    5) Multi-institutional randomized phase-3 trial comparing cancer stem cell-targeted vs physician-choice treatments in patients with recurrent high-grade glioma (NCT03632135). Annual Meeting of the American Association for Cancer Research (AACR)<\/strong>, New Orleans, LA, April 8-12, 2022.<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    6) Multi-institutional randomized phase-3 trial comparing cancer stem cell-targeted vs physician-choice treatments in patients with recurrent high-grade glioma (NCT03632135). Annual Meeting of the American Society of Clinical Oncology (ASCO)<\/strong> Chicago, IL, June 3-7, 2022.<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    7) Cancer Stem Cell Assay for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer. Stem Cell Res Dev Ther<\/strong> 2021, 7: 076 DOI: 10.24966\/SRDT-2060\/100076<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    8) Initial Analysis of Phase-III Trial \u2013 Standard Chemotherapy vs. Chemotherapy Guided by a Cancer Stem Cell Test in Recurrent Glioblastoma (NCT03632135). Neuro-Oncology<\/strong>, Volume 22, Issue Supplement_2, November 2020, Page ii50, https:\/\/doi.org\/10.1093\/neuonc\/noaa215.20<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    9) Clinical Relevance of Cancer Stem Cell Cytotoxicity Assay in Guiding Treatment of Glioblastoma. Neuro-Oncology,<\/strong> Volume 22, Issue Supplement_2, November 2020, Page ii200, https:\/\/doi.org\/10.1093\/neuonc\/noaa215.838<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    10) Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer. Transl Oncol.<\/strong> 2020; 13;(12):100860. doi: 10.1016\/j.tranon.2020.100860<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    11) Cancer Stem Cell Chemotherapeutics Assay for Prospective Treatment of Recurrent Glioblastoma and Progressive Anaplastic Glioma: A Single-Institution Case Series. Transl Oncol.<\/strong> 2020 Mar 17;13(4):100755. doi: 10.1016\/j.tranon.2020.100755<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    12) Prospective analysis of cancer stem cells drug response assay for glioblastoma patients. 2018 Neuro-Oncology<\/strong>, Vol 20, Issue suppl_6, 5 November 2018, Pages vi243<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    13) Prospective analysis of cancer stem cells drug response assay for glioblastoma patients. 2018 ASCO<\/strong> Annual Meeting. J Clin Oncol 36, 2018 (suppl; abstr 2057)<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    14) Efficacy of ChemoID guided drug selection for palliative chemotherapy in advanced recurrent high-grade ovarian adenocarcinoma: case study. Translational Medicine Reports<\/strong>, (2017) 1: 6701, 70-75.<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    15) The future of precision medicine in oncology: targeting cancer stem cells. Editorial | Clinics in Oncology<\/strong>, (2017) 2: 1187, 1-3.<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    16) Analysis of Chemopredictive Assay for Targeting Cancer Stem Cells in Glioblastoma Patients. Research Article | Translational Oncology<\/strong>, (2017) 10, 241-254.<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    17) Functional drug response assay for cancer stem cells in the era of precision medicine. Editorial | Translational Medicine Reports<\/strong>, (2017) 1: 6421, 7-10.<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    18) Analysis of chemo-predictive assay for targeting cancer stem cells in 41 glioblastoma patients. 2017 ASCO<\/strong> Annual Meeting. J Clin Oncol 35, 2017 (suppl; abstr e13544)<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    19) A new complementary procedure for patients affected by head and neck cancer: Chemo-predictive assay. Research Article | International Journal of Surgery Case Reports<\/strong>, 26 (2016) 42-46.<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    20) ChemoID assay for glioblastoma. 2015 ASCO <\/strong>Annual Meeting. J Clin Oncol 33, 2015 (suppl; abstr e13028)<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    21) Chemo-Predictive Assay for Targeting Cancer Stem-Like Cells in Patients Affected by Brain Tumors. Research Article | published 21 Aug 2014 | PLOS ONE<\/strong>10.1371\/journal.pone.0105710<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    22) Novel chemosensitivity assay for targeting cancer stem-like cells in brain tumors. 2014 ASCO<\/strong> Annual Meeting. J Clin Oncol 32, 2014 (suppl; abstr e13012)<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    23) ChemoID assay for patients with primary brain tumors. 2013 ASCO<\/strong> Annual Meeting. J Clin Oncol 31, 2013 (suppl; abstr 2089)<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    24) ChemoID assay for anaplastic spinal ependymoma. 2013 ASCO Annual Meeting. J Clin Oncol <\/strong>31, 2013 (suppl; abstr e13040)<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n\n\n\n

    25) Rapid Selection and Proliferation of CD133(+) Cells from Cancer Cell Lines: Chemotherapeutic Implications. Research Article | published 08 Apr 2010 | PLOS ONE<\/strong>10.1371\/journal.pone.00100351)<\/p>\n\n\n\n

    <\/a><\/p>\n\n\n\n

    PDF<\/a><\/h3>\n","protected":false},"excerpt":{"rendered":"

    1. ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial. Nature npj Precision. Oncology. 9, 86 (2025). PDF : https:\/\/doi.org\/10.1038\/s41698-025-00874-0 2. A New and Effective Procedure for Advanced Oral Cancer Therapy: The Potential of a Cancer Stem Cell Assay in Guiding Chemotherapy. Transl Med UniSa. 2023 Dec 8;25(1):16-27. doi: 10.37825\/2239-9747.1042. […]<\/p>\n","protected":false},"author":268,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-19","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/mupages.marshall.edu\/valluri\/wp-json\/wp\/v2\/pages\/19","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mupages.marshall.edu\/valluri\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/mupages.marshall.edu\/valluri\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/mupages.marshall.edu\/valluri\/wp-json\/wp\/v2\/users\/268"}],"replies":[{"embeddable":true,"href":"https:\/\/mupages.marshall.edu\/valluri\/wp-json\/wp\/v2\/comments?post=19"}],"version-history":[{"count":3,"href":"https:\/\/mupages.marshall.edu\/valluri\/wp-json\/wp\/v2\/pages\/19\/revisions"}],"predecessor-version":[{"id":44,"href":"https:\/\/mupages.marshall.edu\/valluri\/wp-json\/wp\/v2\/pages\/19\/revisions\/44"}],"wp:attachment":[{"href":"https:\/\/mupages.marshall.edu\/valluri\/wp-json\/wp\/v2\/media?parent=19"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}